Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13,698.99% | 12,751.20% | 13,669.75% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13,698.99% | 12,751.20% | 13,669.75% | -- | -- |
| Cost of Revenue | 1,052.91% | 1,196.04% | 2,208.98% | -- | -- |
| Gross Profit | 518.93% | 241.49% | -703.64% | -- | -- |
| SG&A Expenses | 43.12% | 35.70% | 22.43% | 1.27% | 2.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.14% | 16.50% | 14.80% | 12.27% | 15.76% |
| Operating Income | 14.17% | 3.67% | -7.21% | -11.82% | -15.46% |
| Income Before Tax | 16.20% | 4.27% | -6.38% | -10.42% | -13.04% |
| Income Tax Expenses | 18.71% | -257.27% | -1,130.19% | -- | -- |
| Earnings from Continuing Operations | 16.18% | 5.31% | -5.10% | -9.23% | -12.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.18% | 5.31% | -5.10% | -9.23% | -12.16% |
| EBIT | 14.17% | 3.67% | -7.21% | -11.82% | -15.46% |
| EBITDA | 17.54% | 7.11% | -3.35% | -8.20% | -12.73% |
| EPS Basic | 31.46% | 28.07% | 25.12% | 24.45% | 23.77% |
| Normalized Basic EPS | 30.90% | 26.80% | 23.80% | 23.29% | 22.77% |
| EPS Diluted | 31.46% | 28.07% | 25.12% | 24.45% | 23.77% |
| Normalized Diluted EPS | 30.90% | 26.80% | 23.80% | 23.29% | 22.77% |
| Average Basic Shares Outstanding | 23.33% | 30.81% | 38.39% | 43.10% | 47.56% |
| Average Diluted Shares Outstanding | 23.33% | 30.81% | 38.39% | 43.10% | 47.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |